Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients

Author:

Romano Alessandra123,Chiarenza Annalisa2,Conticello Concetta2,Cavalli Maide2,Vetro Calogero1,Di Raimondo Cosimo1,Cunsolo Rosario4,Palumbo Giuseppe Alberto2,Di Raimondo Francesco12

Affiliation:

1. Department of Clinical and Molecular Biomedicine; Section of Haematology; University of Catania; Catania Italy

2. Division of Hematology; Azienda Policlinico-OVE; Catania Italy

3. Fondazione Umberto Veronesi; Rome Italy

4. Medical & Regulatory Affairs Department; Azienda Policlinico-OVE; Catania Italy

Funder

Fondazione Veronesi

Publisher

Wiley

Subject

Hematology,General Medicine

Reference29 articles.

1. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review;Kumar;Am J Hematol,2011

2. Bortezomib for the treatment of previously untreated multiple myeloma;Romano;Immunotherapy,2013

3. Multiple myeloma: treatment evolution;San Miguel;Hematology,2012

4. Pegylated liposomal doxorubicin in salvage chemotherapy for multiple myeloma patients;Romano;Curr Canc Ther Rev,2013

5. NCCN clinical practice guidelines in oncology: multiple myeloma;Anderson;J Natl Compr Canc Netw,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3